Goldman Sachs Stands Firm on ALHC Buy Rating Amid Strong Q2 Beat

Goldman Sachs analyst Scott Fidel has maintained his bullish stance on ALHC stock by reaffirming a Buy rating. His decision was influenced by Alignment Healthcare's impressive second-quarter results, which exceeded Goldman Sachs and consensus expectations across key metrics.

The company's strong operational performance and earnings power are highlighted as key factors in Fidel's positive assessment. Specifically, Alignment Healthcare delivered second-quarter revenue, membership, adjusted gross profit, and adjusted EBITDA that surpassed forecasts, demonstrating effective medical cost management and solid membership growth.

Management also raised its full-year 2026 guidance with higher midpoints across key metrics and a notably stronger implied fourth-quarter EBITDA versus Street forecasts. While third-quarter guidance was softer due to seasonality, a higher-acuity member mix, and deliberate spending on clinical and growth initiatives, Fidel views these investments as crucial for long-term expansion.

Fidel's Buy rating is supported by his 63.80% success rate on recommended stocks and an average return of 7.9%. Another report released today maintains a similar outlook with KeyBanc reaffirming its Buy rating and setting a price target of $28.00, although Goldman Sachs maintains its price target at $25.